Arrowhead Pharmaceuticals, Inc. Stock price
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.6 USD | -0.35% | +1.31% | -6.54% |
Mar. 25 | Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran | CI |
Mar. 08 | Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise | MT |
Financials (USD)
Sales 2024 * | 126M | Sales 2025 * | 181M | Capitalization | 3.54B |
---|---|---|---|---|---|
Net income 2024 * | -313M | Net income 2025 * | -300M | EV / Sales 2024 * | 24.8 x |
Net cash position 2024 * | 426M | Net cash position 2025 * | 313M | EV / Sales 2025 * | 17.9 x |
P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-11.3
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.5% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | -0.35% | ||
1 week | +1.31% | ||
Current month | -10.90% | ||
1 month | -15.88% | ||
3 months | -7.74% | ||
6 months | +6.20% | ||
Current year | -6.54% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 28.6 | -0.35% | 589,030 |
24-03-27 | 28.7 | +3.09% | 537,605 |
24-03-26 | 27.84 | -0.18% | 710,015 |
24-03-25 | 27.89 | +2.50% | 517,415 |
24-03-22 | 27.21 | -3.61% | 712,149 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.54% | 3.54B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |